Deep Drug–Target Binding Affinity Prediction Base on Multiple Feature Extraction and Fusion
ACS Omega · 21.01.2025 · 10 (2) · 2020-2032
DOI: 10.1021/acsomega.4c08048 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 10.01.2025. Verfasst von Zepeng Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Computer Science and Technology, Zhejiang Sci-Tech University, Hangzhou 310018, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Key Research and Development Program of Ningxia, Key Research and Development Program of Zhejiang Province.
Abstract (Originalsprache)
Accurate drug-target binding affinity (DTA) prediction is crucial in drug discovery. Recently, deep learning methods for DTA prediction have made significant progress. However, there are still two challenges: (1) recent models always ignore the correlations in drug and target data in the drug/target representation process and (2) the interaction learning of drug-target pairs always is by simple concatenation, which is insufficient to explore their fusion. To overcome these challenges, we propose an end-to-end sequence-based model called BTDHDTA. In the feature extraction process, the bidirectional gated recurrent unit (GRU), transformer encoder, and dilated convolution are employed to extract global, local, and their correlation patterns of drug and target input. Additionally, a module combining convolutional neural networks with a Highway connection is introduced to fuse drug and protein deep features. We evaluate the performance of BTDHDTA on three benchmark data sets (Davis, KIBA, and Metz), demonstrating its superiority over several current state-of-the-art methods in key metrics such as Mean Squared Error (MSE), Concordance Index (CI), and Regression toward the mean (R m 2). The results indicate that our method achieves a better performance in DTA prediction. In the case study, we use the BTDHDTA model to predict the binding affinities between 3137 FDA-approved drugs and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication-related proteins, validating the model's effectiveness in practical scenarios.
Autor:innen und Institutionen
- School of Computer Science and Technology, Zhejiang Sci-Tech University, Hangzhou 310018, China.
- Longgang Research Institute, Zhejiang Sci-Tech University, Longgang 325000, Zhejiang, China.
ORCID-Profile: Yuni Zeng
Förderung
- National Key Research and Development Program of China
- Key Research and Development Program of Ningxia
- Key Research and Development Program of Zhejiang Province
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Li, Z., Zeng, Y., Jiang, M., & Wei, B. (2025). Deep Drug–Target Binding Affinity Prediction Base on Multiple Feature Extraction and Fusion. ACS Omega, 10(2), 2020-2032. https://doi.org/10.1021/acsomega.4c08048
Vancouver
Li Z, Zeng Y, Jiang M, Wei B. Deep Drug–Target Binding Affinity Prediction Base on Multiple Feature Extraction and Fusion. ACS Omega. 2025;10(2):2020-2032. doi:10.1021/acsomega.4c08048
BibTeX
@article{Li2025,
author = {Li, Zepeng and Zeng, Yuni and Jiang, Mingfeng and Wei, Bo},
title = {Deep Drug–Target Binding Affinity Prediction Base on Multiple Feature Extraction and Fusion},
journal = {ACS Omega},
year = {2025},
volume = {10},
number = {2},
pages = {2020--2032},
doi = {10.1021/acsomega.4c08048}
}
EUVIMED